TJ244R3 - (-)-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(111)-pyrimidin-2-one mixture of its enantiomers method of its preparation method of treatment - Google Patents

(-)-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(111)-pyrimidin-2-one mixture of its enantiomers method of its preparation method of treatment

Info

Publication number: TJ244R3
Authority: TJ; Tajikistan
Prior art keywords: oxathiolan; pyrimidin; hydroxymethyl; fluoro; amino
Prior art date: 1991-08-01

Application number

TJ94000128A

Other languages

English (en)

Inventor

Gervais Dionne

Original Assignee

Iaf Biochem Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-08-01

Filing date

1994-12-15

Publication date

1999-11-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10699340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TJ244(R3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-12-15 Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int

1994-12-15 Priority to TJ94000128A priority Critical patent/TJ244R3/xx

1999-11-24 Publication of TJ244R3 publication Critical patent/TJ244R3/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/38—Nucleosides
- C12P19/40—Nucleosides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/001—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by metabolizing one of the enantiomers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/006—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Molecular Biology (AREA)
Analytical Chemistry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)

TJ94000128A 1991-08-01 1994-12-15 (-)-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(111)-pyrimidin-2-one mixture of its enantiomers method of its preparation method of treatment TJ244R3 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
TJ94000128A TJ244R3 (en)	1991-08-01	1994-12-15	(-)-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(111)-pyrimidin-2-one mixture of its enantiomers method of its preparation method of treatment

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB919116601A GB9116601D0 (en)	1991-08-01	1991-08-01	1,3-oxathiolane nucleoside analogues
PCT/CA1992/000321 WO1993003027A1 (en)	1991-08-01	1992-07-24	1,3-oxathiolane nucleoside analogues
TJ94000128A TJ244R3 (en)	1991-08-01	1994-12-15	(-)-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(111)-pyrimidin-2-one mixture of its enantiomers method of its preparation method of treatment

Publications (1)

Publication Number	Publication Date
TJ244R3 true TJ244R3 (en)	1999-11-24

Family

ID=10699340

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TJ94000128A TJ244R3 (en)	1991-08-01	1994-12-15	(-)-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(111)-pyrimidin-2-one mixture of its enantiomers method of its preparation method of treatment

Country Status (40)

Country	Link
US (2)	US5538975A (ro)
EP (2)	EP0526253B1 (ro)
JP (1)	JP2960778B2 (ro)
KR (1)	KR100242454B1 (ro)
CN (5)	CN101074228A (ro)
AP (1)	AP321A (ro)
AT (2)	ATE227720T1 (ro)
AU (1)	AU659668B2 (ro)
BG (1)	BG61693B1 (ro)
CA (2)	CA2114221C (ro)
CZ (1)	CZ283765B6 (ro)
DE (2)	DE69232845T2 (ro)
DK (2)	DK0526253T3 (ro)
EE (1)	EE03002B1 (ro)
EG (1)	EG20193A (ro)
ES (2)	ES2186667T3 (ro)
FI (1)	FI940435L (ro)
GB (1)	GB9116601D0 (ro)
GE (1)	GEP20002094B (ro)
HN (1)	HN1997000118A (ro)
HU (2)	HUT70030A (ro)
IL (1)	IL102616A (ro)
MA (1)	MA22919A1 (ro)
MD (1)	MD1434C2 (ro)
MX (1)	MX9204474A (ro)
NO (3)	NO300842B1 (ro)
NZ (1)	NZ243637A (ro)
OA (1)	OA09883A (ro)
PH (1)	PH30983A (ro)
PT (2)	PT526253E (ro)
RS (1)	RS49993B (ro)
RU (1)	RU2126405C1 (ro)
SG (1)	SG68541A1 (ro)
SK (1)	SK280131B6 (ro)
TJ (1)	TJ244R3 (ro)
TN (1)	TNSN92070A1 (ro)
TW (2)	TWI232217B (ro)
WO (1)	WO1993003027A1 (ro)
YU (1)	YU49259B (ro)
ZA (1)	ZA925668B (ro)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6903224B2 (en)	1988-04-11	2005-06-07	Biochem Pharma Inc.	Substituted 1,3-oxathiolanes
US5204466A (en) *	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) *	1990-02-01	1994-01-04	Emory University	Method of synthesis of 1,3-dioxolane nucleosides
US5914331A (en)	1990-02-01	1999-06-22	Emory University	Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6703396B1 (en)	1990-02-01	2004-03-09	Emory University	Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5827727A (en)	1990-02-01	1998-10-27	Emory University	Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5925643A (en) *	1990-12-05	1999-07-20	Emory University	Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) *	1990-12-05	1995-08-22	Emory University	Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6812233B1 (en)	1991-03-06	2004-11-02	Emory University	Therapeutic nucleosides
US5817667A (en) *	1991-04-17	1998-10-06	University Of Georgia Research Foudation	Compounds and methods for the treatment of cancer
GB9116601D0 (en) *	1991-08-01	1991-09-18	Iaf Biochem Int	1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) *	1992-12-24	1993-02-17	Iaf Biochem Int	Dideoxy nucleoside analogues
GB9311709D0 (en) *	1993-06-07	1993-07-21	Iaf Biochem Int	Stereoselective synthesis of nucleoside analogues using bicycle intermediate
CA2637774C (en)	1993-09-10	2011-07-19	Emory University	Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en)	1993-09-10	2002-08-29	Gilles Gosselin	2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) *	1994-01-28	1996-12-24	Univ. Of Ga Research Foundation	L-nucleosides
IL113432A (en)	1994-04-23	2000-11-21	Glaxo Group Ltd	Process for the diastereoselective synthesis of nucleoside analogues
IL115156A (en)	1994-09-06	2000-07-16	Univ Georgia	Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en)	1995-01-27	2002-05-21	Emory University	[5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en)	1995-01-27	1997-12-30	Emory University	Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) *	1995-01-30	1998-09-15	Yale University	L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
GB9506644D0 (en) *	1995-03-31	1995-05-24	Wellcome Found	Preparation of nucleoside analogues
ATE346651T1 (de)	1995-06-07	2006-12-15	Univ Emory	Nucleoside mit anti-hepatitis b virus wirksamkeit
TW505653B (en) *	1996-02-26	2002-10-11	Meiji Seika Co	Triterpene derivatives possessing an effect of treating liver diseases and pharmacentical compositions containing the same
US5753789A (en) *	1996-07-26	1998-05-19	Yale University	Oligonucleotides containing L-nucleosides
ATE267198T1 (de) *	1997-03-19	2004-06-15	Univ Emory	Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden
WO1998044913A2 (en)	1997-04-07	1998-10-15	Triangle Pharmaceuticals, Inc.	Compositions containing mkc-442 in combination with other antiviral agents
JP4249393B2 (ja)	1998-08-12	2009-04-02	トライアングル・ファーマシューティカルズ，インコーポレイテッド	１，３−オキサチオランヌクレオチドの製造方法
US6979561B1 (en)	1998-10-09	2005-12-27	Gilead Sciences, Inc.	Non-homogeneous systems for the resolution of enantiomeric mixtures
ES2314157T3 (es) *	1998-11-02	2009-03-16	Gilead Sciences, Inc.	Terapia de combinacion para tratar el virus de la hepatitis b.
US6436948B1 (en)	2000-03-03	2002-08-20	University Of Georgia Research Foundation Inc.	Method for the treatment of psoriasis and genital warts
CA2405502A1 (en) *	2000-03-29	2001-10-04	Georgetown University	Method of treating hepatitis delta viral infection
CA2308559C (en)	2000-05-16	2005-07-26	Brantford Chemicals Inc.	1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
PT1574512E (pt) *	2001-03-01	2008-03-05	Abbott Lab	Formas polimórficas e outras formas cristalinas de cis-ftc
AU2008202336B2 (en) *	2001-03-01	2011-11-10	Abbvie Inc.	Polymorphic and other crystalline forms of cis-FTC
WO2003051298A2 (en) *	2001-12-14	2003-06-26	Pharmasset Ltd.	Preparation of intermediates useful in the synthesis of antiviral nucleosides
EA015145B1 (ru)	2003-01-14	2011-06-30	Джилид Сайэнс, Инк.	Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции
ITMI20030578A1 (it)	2003-03-24	2004-09-25	Clariant Lsm Italia Spa	Processo ed intermedi per la preparazione di emtricitabina
TWI471145B (zh)	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
TWI375560B (en)	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CN100360528C (zh) *	2005-08-31	2008-01-09	四川大学	4-氨基-1-(2-羟甲基-1,3-氧硫杂环戊烷-5-基)-2(1h)-嘧啶酮的制备方法
WO2007077505A2 (en) *	2005-12-30	2007-07-12	Ranbaxy Laboratories Limited	Crystalline l-menthyl (2r, 5s)-5-(4-amino-5-fluoro-2-oxo-2h-pyrimidin-1-yl)[1, 3]oxathiolan-2-carboxylate and process for preparation thereof
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
JP6104504B2 (ja) *	2008-12-23	2017-03-29	ギリアドファーマセットエルエルシー	ヌクレオシド類似体
TW201026715A (en) *	2008-12-23	2010-07-16	Pharmasset Inc	Nucleoside phosphoramidates
CL2009002206A1 (es)	2008-12-23	2011-08-26	Gilead Pharmasset Llc	Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
WO2010113039A1 (en) *	2009-04-03	2010-10-07	Medical Research Council	Mutants of activation-induced cytidine deaminase (aid) and methods of use
EP2377862A1 (en)	2010-03-29	2011-10-19	Esteve Química, S.A.	Process for obtaining emtricitabine
CL2011000716A1 (es)	2010-03-31	2012-04-20	Gilead Pharmasset Llc	Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
EP3449994B1 (en)	2012-01-10	2024-08-07	C.C. Jensen A/S	System for cleaning degraded oil
US11116737B1 (en)	2020-04-10	2021-09-14	University Of Georgia Research Foundation, Inc.	Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5668674A (en) *	1979-11-08	1981-06-09	Shionogi & Co Ltd	5-fluorouracil derivative
DE2950317A1 (de) *	1979-12-14	1981-06-19	Agfa-Gevaert Ag, 5090 Leverkusen	Elektrothermographische vorrichtung
US5047407A (en) *	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5270315A (en) *	1988-04-11	1993-12-14	Biochem Pharma Inc.	4-(purinyl bases)-substituted-1,3-dioxlanes
US5466806A (en) *	1989-02-08	1995-11-14	Biochem Pharma Inc.	Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
ES2196004T3 (es) *	1989-02-08	2003-12-16	Iaf Biochem Int	Procedimiento para preparar 1,3-oxatiolanos sustituidos con propiedades antivirales.
US5204466A (en) *	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) *	1990-02-01	1994-01-04	Emory University	Method of synthesis of 1,3-dioxolane nucleosides
GB9009861D0 (en) *	1990-05-02	1990-06-27	Glaxo Group Ltd	Chemical compounds
US5444063A (en) *	1990-12-05	1995-08-22	Emory University	Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5248776A (en) *	1990-12-05	1993-09-28	University Of Georgia Research Foundation, Inc.	Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
AU9125991A (en) *	1990-12-05	1992-07-08	University Of Georgia Research Foundation, Inc., The	Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides
IL100965A (en) *	1991-02-22	1999-12-31	Univ Emory	2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
GB9104740D0 (en) *	1991-03-06	1991-04-17	Wellcome Found	Antiviral nucleoside combination
CA2105486C (en) *	1991-03-06	2003-10-28	George Robert Painter Iii	Therapeutic nucleosides
WO1992018517A1 (en) *	1991-04-17	1992-10-29	Yale University	Method of treating or preventing hepatitis b virus
GB9111902D0 (en) *	1991-06-03	1991-07-24	Glaxo Group Ltd	Chemical compounds
GB9116601D0 (en) *	1991-08-01	1991-09-18	Iaf Biochem Int	1,3-oxathiolane nucleoside analogues

1991
- 1991-08-01 GB GB919116601A patent/GB9116601D0/en active Pending
1992
- 1992-07-20 NZ NZ243637A patent/NZ243637A/en unknown
- 1992-07-23 IL IL10261692A patent/IL102616A/en not_active IP Right Cessation
- 1992-07-24 US US08/190,203 patent/US5538975A/en not_active Expired - Fee Related
- 1992-07-24 SK SK104-94A patent/SK280131B6/sk not_active IP Right Cessation
- 1992-07-24 CZ CZ94203A patent/CZ283765B6/cs not_active IP Right Cessation
- 1992-07-24 GE GEAP19922643A patent/GEP20002094B/en unknown
- 1992-07-24 AU AU23408/92A patent/AU659668B2/en not_active Expired
- 1992-07-24 MD MD95-0114A patent/MD1434C2/ro unknown
- 1992-07-24 RU RU94013464A patent/RU2126405C1/ru active
- 1992-07-24 KR KR1019940700260A patent/KR100242454B1/ko not_active Expired - Lifetime
- 1992-07-24 CA CA002114221A patent/CA2114221C/en not_active Expired - Lifetime
- 1992-07-24 CA CA2682254A patent/CA2682254C/en not_active Expired - Lifetime
- 1992-07-24 FI FI940435A patent/FI940435L/fi not_active Application Discontinuation
- 1992-07-24 JP JP5503131A patent/JP2960778B2/ja not_active Expired - Lifetime
- 1992-07-24 HU HU9400285A patent/HUT70030A/hu unknown
- 1992-07-24 WO PCT/CA1992/000321 patent/WO1993003027A1/en not_active Ceased
- 1992-07-28 ZA ZA925668A patent/ZA925668B/xx unknown
- 1992-07-29 MA MA22897A patent/MA22919A1/fr unknown
- 1992-07-29 PH PH44737A patent/PH30983A/en unknown
- 1992-07-30 EG EG42992A patent/EG20193A/xx active
- 1992-07-31 TW TW088109613A patent/TWI232217B/zh not_active IP Right Cessation
- 1992-07-31 RS YUP-723/03A patent/RS49993B/sr unknown
- 1992-07-31 TW TW081106093A patent/TW366347B/zh not_active IP Right Cessation
- 1992-07-31 AP APAP/P/1992/000414A patent/AP321A/en active
- 1992-07-31 TN TNTNSN92070A patent/TNSN92070A1/fr unknown
- 1992-07-31 MX MX9204474A patent/MX9204474A/es active IP Right Grant
- 1992-07-31 YU YU74992A patent/YU49259B/sh unknown
- 1992-08-01 CN CNA2006100999092A patent/CN101074228A/zh active Pending
- 1992-08-01 CN CN92108995A patent/CN1034810C/zh not_active Expired - Lifetime
- 1992-08-01 CN CNA2006100999088A patent/CN101066970A/zh active Pending
- 1992-08-03 DK DK92307051T patent/DK0526253T3/da active
- 1992-08-03 AT AT92307051T patent/ATE227720T1/de active
- 1992-08-03 ES ES92307051T patent/ES2186667T3/es not_active Expired - Lifetime
- 1992-08-03 SG SG1996001043A patent/SG68541A1/en unknown
- 1992-08-03 DE DE69232845T patent/DE69232845T2/de not_active Expired - Lifetime
- 1992-08-03 EP EP92307051A patent/EP0526253B1/en not_active Expired - Lifetime
- 1992-08-03 PT PT92307051T patent/PT526253E/pt unknown
- 1992-08-03 DK DK01119636.7T patent/DK1155695T3/da active
- 1992-08-03 AT AT01119636T patent/ATE448787T1/de active
- 1992-08-03 PT PT01119636T patent/PT1155695E/pt unknown
- 1992-08-03 EP EP01119636A patent/EP1155695B1/en not_active Expired - Lifetime
- 1992-08-03 DE DE69233776T patent/DE69233776D1/de not_active Expired - Lifetime
- 1992-08-03 ES ES01119636T patent/ES2335968T3/es not_active Expired - Lifetime
1994
- 1994-01-31 NO NO940322A patent/NO300842B1/no not_active IP Right Cessation
- 1994-02-01 OA OA60465A patent/OA09883A/en unknown
- 1994-02-28 BG BG98616A patent/BG61693B1/bg unknown
- 1994-10-20 EE EE9400261A patent/EE03002B1/xx not_active IP Right Cessation
- 1994-12-15 TJ TJ94000128A patent/TJ244R3/xx unknown
1995
- 1995-06-07 US US08/487,452 patent/US5618820A/en not_active Expired - Fee Related
- 1995-06-30 HU HU95P/P00707P patent/HU211333A9/hu unknown
- 1995-11-03 CN CN95118741A patent/CN1074924C/zh not_active Expired - Lifetime
1997
- 1997-08-18 HN HN1997000118A patent/HN1997000118A/es unknown
2000
- 2000-05-26 CN CNB001179012A patent/CN100542535C/zh not_active Expired - Lifetime
2005
- 2005-08-19 NO NO2005017C patent/NO2005017I2/no not_active Application Discontinuation
2008
- 2008-06-12 NO NO2008009C patent/NO2008009I1/no unknown

Also Published As

Publication number	Publication date
AP321A (en)	1994-02-28
PT1155695E (pt)	2010-02-02
CN1070191A (zh)	1993-03-24
IL102616A (en)	1996-10-31
EP0526253A1 (en)	1993-02-03
HK1038189A1 (en)	2002-03-08
GB9116601D0 (en)	1991-09-18
TNSN92070A1 (fr)	1993-06-08
DE69232845D1 (de)	2002-12-19
MD1434C2 (ro)	2000-12-31
DE69232845T2 (de)	2003-04-24
MD950114A (ro)	1996-06-28
GEP20002094B (en)	2000-05-10
NZ243637A (en)	1995-03-28
NO2005017I2 (no)	2007-10-01
WO1993003027A1 (en)	1993-02-18
HN1997000118A (es)	1999-11-12
YU74992A (sh)	1995-12-04
AU659668B2 (en)	1995-05-25
SK10494A3 (en)	1994-12-07
IL102616A0 (en)	1993-01-14
ATE227720T1 (de)	2002-11-15
CN1302612A (zh)	2001-07-11
MA22919A1 (fr)	1993-04-01
US5538975A (en)	1996-07-23
TWI232217B (en)	2005-05-11
FI940435A7 (fi)	1994-01-28
CZ20394A3 (en)	1994-07-13
CN101066970A (zh)	2007-11-07
HU211333A9 (en)	1995-11-28
AU2340892A (en)	1993-03-02
JPH07500317A (ja)	1995-01-12
CN101074228A (zh)	2007-11-21
DK0526253T3 (da)	2003-03-17
PH30983A (en)	1997-12-23
EG20193A (en)	1997-10-30
CA2114221A1 (en)	1993-02-18
PT526253E (pt)	2003-03-31
EP1155695A1 (en)	2001-11-21
ATE448787T1 (de)	2009-12-15
NO940322L (no)	1994-03-21
AP9200414A0 (en)	1992-07-31
NO2008009I1 (no)	2008-06-30
EP1155695B1 (en)	2009-11-18
NO300842B1 (no)	1997-08-04
EP0526253B1 (en)	2002-11-13
HUT70030A (en)	1995-09-28
CA2682254A1 (en)	1993-02-18
JP2960778B2 (ja)	1999-10-12
DE69233776D1 (de)	2009-12-31
BG98616A (bg)	1995-03-31
HU9400285D0 (en)	1994-05-30
YU49259B (sh)	2004-12-31
NO2005017I1 (no)	2005-09-05
KR100242454B1 (ko)	2000-03-02
CA2114221C (en)	2009-12-22
CN1132073A (zh)	1996-10-02
NO940322D0 (no)	1994-01-31
RS49993B (sr)	2008-09-29
OA09883A (en)	1994-09-15
FI940435A0 (fi)	1994-01-28
FI940435L (fi)	1994-01-28
SG68541A1 (en)	1999-11-16
CN1074924C (zh)	2001-11-21
MD1434B2 (ro)	2000-03-31
CA2682254C (en)	2012-02-21
ES2186667T3 (es)	2003-05-16
YU72303A (sh)	2006-05-25
MX9204474A (es)	1993-12-01
BG61693B1 (bg)	1998-03-31
DK1155695T3 (da)	2010-04-06
TW366347B (en)	1999-08-11
CZ283765B6 (cs)	1998-06-17
US5618820A (en)	1997-04-08
ES2335968T3 (es)	2010-04-07
HK1008672A1 (en)	1999-05-14
EE03002B1 (et)	1997-06-16
SK280131B6 (sk)	1999-08-06
CN100542535C (zh)	2009-09-23
RU2126405C1 (ru)	1999-02-20
ZA925668B (en)	1993-04-28
CN1034810C (zh)	1997-05-07

Publication	Publication Date	Title
NZ238017A (en)	1994-06-27	(-)-cis-4-amino-1 -(2-hydroxymethyl -1,3-oxathiolan-5-yl) -(1h)- pyrimidin-2-one, preparation and pharmaceutical compositions
EG20193A (en)	1997-10-30	Process for preparing of 1,3- oxathiolane nucleoside analogues
PH25786A (en)	1991-11-05	Skin cleansing, mositurizing composition , method of using same composition
HU9302377D0 (en)	1993-11-29	Method for preparing medical preparatives of antiviral effect as well as one for resolving 2-(hydroxi-methyl)-5-(5-fluorine-cytosine-1-yl)-1,3-oxathiolane
NZ232421A (en)	1993-10-26	Purine or pyrimidine substituted 1,3-oxathiolane derivatives; preparatory process, intermediates and pharmaceutical compositions
HUT49592A (en)	1989-10-30	Process for producing bis/hydroxymethyl/-cyclobutyl-purines and pyrimidines, as well as pharmaceutical compositions comprising same
CA2311988A1 (en)	1992-12-04	Crystalline oxathiolane derivatives
FI20030933A7 (fi)	2003-06-24	1,3-oksatiolaani ja menetelmä sen valmistamiseksi
HUT65374A (en)	1994-05-02	Process for producing of dialkylene-piperidino compounds,their enantiomers and pharmaceutical compositions comprising them
BR9503812A (pt)	1996-04-16	Composto composição farmacêutica utilização método de tratamento de um ser humano processo para a preparação de um composto
DE69400256D1 (de)	1996-07-25	Verfahren zur Herstellung von mit Carbonat angereicherten Hydroxyapatit Zusammensetzungen
AU6924796A (en)	1997-03-12	1,3-oxathiolane nucleoside analogues in the treatment of hepatitis c
PL295673A2 (en)	1993-05-17	Method of obtaining novel derivatives of 1,4-benzodioxane
MA20084A1 (fr)	1984-12-31	Derives de la furo-(3,4-c)-pyridine leur preparation et compositions therapeutiques contenant ces derives.
HUT48216A (en)	1989-05-29	Insecticidal, nematocidal, coccidiostatic compositions comprising n-phenylpyrazole derivatives and process for producing the active ingredients
HUT54345A (en)	1991-02-28	Process for producing new, antiarrhythmic, sulfur-containing cyanophenol derivatives and medical compositions comprising same
PL300016A1 (en)	1994-04-05	1,4 derivatives of benzodioxane, method of obtaining them as well as pharmaceutical preparation and method of obtaining same
MA22154A1 (fr)	1991-12-31	Methode de preparation de derives de furo (3,4-c) pyridine sous forme non- racemique
IL111580A (en)	1999-10-28	Use of melatonin derivatives in the preparation of pharmaceutical compositions for use in treating sleep disorders
HUT54358A (en)	1991-02-28	Process for producing substituted 1,3,5-triazinetrione derivatives and medical compositions comprising such compounds as active ingredient
HU914049D0 (en)	1992-07-28	New leucotriene-b4 derivatives, method for producing them and application of said compounds as medicament
HUT44694A (en)	1988-04-28	Process for producing benzthiazinone derivatives, and fungicide compositions containing them as active components
GB9221234D0 (en)	1992-11-25	Stemmed flower-like decorating
ITAL910005A0 (it)	1991-07-12	Processo per la realizzazione di strutture protesiche dentali.
HU9203939D0 (en)	1993-03-29	Isoxazolyl-imidazole derivatives, method for producing them and their application as medicament